39621-00-6

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Dichloro-4-picoline is used as a key intermediate in the synthesis of substituted phenoxymethyl benzoic acids and related products. These synthesized compounds serve as modulators of Mas-related G-protein receptor X4 (MrgprX4), which are involved in various physiological processes, including pain sensation and immune response regulation. By modulating these receptors, the synthesized compounds can potentially be used in the development of therapeutics for pain management and other related conditions.
Used in Chemical Synthesis:
Due to its unique chemical structure, 2,6-Dichloro-4-picoline can be utilized as a building block in the synthesis of various organic compounds. Its reactivity with different functional groups allows for the creation of a wide range of molecules with diverse applications, such as agrochemicals, dyes, and other specialty chemicals.
Used in Research and Development:
2,6-Dichloro-4-picoline can also be employed as a research tool in the field of organic chemistry. Its unique properties make it an interesting candidate for studying reaction mechanisms, exploring new synthetic routes, and developing novel compounds with potential applications in various industries.

InChI:InChI=1/C6H5Cl2N/c1-4-2-5(7)9-6(8)3-4/h2-3H,1H3

Upstream product

• 824-72-6 P,P-dichlorophenylphosphine oxide 
• 4664-16-8 4-methyl-2,6-dihydroxypyridine 
• 2402-78-0 2,6-dichloropyridine 
• 74-88-4 methyl iodide 
• 512-56-1 trimethyl phosphite 
• 408492-27-3 2,6-dichloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 
• 80-48-8 methyl p-toluene sulfonate 
• 3678-62-4 2-chloro-4-picoline 
• 98027-84-0 2,6-dichloro-4-iodopyridine 
• 823-96-1 Trimethylboroxine 
• 52313-61-8 2-chloro-4-methylpyridin-N-oxide 

Downstream Products

• 770718-74-6 C₁₆H₁₅Cl₂NO₃ 
• 1239363-22-4 (S)-6-chloro-N-[1-(4-fluorophenyl)ethyl]-4-methyl-2-amine 
• 1439923-21-3 1-(6-chloro-4-methylpyridin-2-yl)-N-{[2-(trifluoromethyl)phenyl]methyl}piperidine-4-carboxamide 
• 1239360-59-8 (S)-N₂-[1-(4-fluorophenyl)ethyl]-4-methyl-N₆-(pyrazin-2-yl)pyridine-2,6-diamine 
• 4566-82-9 dimethyl 4-methylpyridine-2,6-dicarboxylate 
• 69971-39-7 methyl 6-(hydroxymethyl)-4-methylpicolinate 
• 1429913-23-4 N-benzyl-4-methyl-6-(2H-1,2,3-triazole-2-yl)pyridine-2-amine 
• 1429913-24-5 N-benzyl-4-methyl-6-(1H-1,2,3-triazole-2-yl)pyridine-2-amine 

Relevant academic research and scientific papers

Trimethylphosphate as a Methylating Agent for Cross Coupling: A Slow-Release Mechanism for the Methylation of Arylboronic Esters

A methyl group on an arene, despite its small size, can have a profound influence on biologically active molecules. Typical methods to form a methylarene involve strong nucleophiles or strong and often toxic electrophiles. We report a strategy for a new, highly efficient, copper and iodide co-catalyzed methylation of aryl- and heteroarylboronic esters with the mild, nontoxic reagent trimethylphosphate, which has not been used previously in coupling reactions. We show that it reacts in all cases tested in yields that are higher than those of analogous copper-catalyzed reactions of MeOTs or MeI. The combination of C-H borylation and this methylation with trimethylphosphate provides a new approach to the functionalization of inert C-H bonds and is illustrated by late-stage methylation of four medicinally active compounds. In addition, reaction on a 200 mmol scale demonstrates reliability of this method. Mechanistic studies show that the reaction occurs by a slow release of methyl iodide by reaction of PO(OMe)3 with iodide catalyst, rather than the typical direct oxidative addition to a metal center. The low concentration of the reactive electrophile enables selective reaction with an arylcopper intermediate, rather than nucleophilic groups on the arylboronate, and binding of tert-butoxide to the boronate inhibits reaction of the electrophile with the tert-butoxide activator to form methyl ether.

Therapeutic agent pcnsl (by machine translation)

The present invention provides a malignant lymphoma therapeutic or preventive agent that comprises as the active ingredient a compound represented by general formula [1] as defined by (I) or (II), or a pharmaceutically acceptable salt thereof. [1] (I) X is CH or N; R1 is a halogen; R2 is a halogen, H, a cyano, a group represented by general formula [9], [9] an optionally substituted heteroaryl, or the like; R3 is H or a hydroxyl; R4 is H or an alkyl; and R5 is H or an alkyl. (II) X is -CRA, RA is -CORB, RB is an optionally substituted amino, alkoxy, or saturated cyclic amino group; R1 is a halogen; R2 is H; R3is H or a hydroxy; R4 is H or an alkyl; and R5 is H or an alkyl.

ANTIVIRAL COMPOUNDS

Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

Novel S1P1 receptor agonists - Part 3: From thiophenes to pyridines

In preceding communications we summarized our medicinal chemistry efforts leading to the identification of potent, selective, and orally active S1P 1 agonists such as the thiophene derivative 1. As a continuation of these efforts, we replaced the thiophene in 1 by a 2-, 3-, or 4-pyridine and obtained less lipophilic, potent, and selective S1P1 agonists (e.g., 2) efficiently reducing blood lymphocyte count in the rat. Structural features influencing the compounds' receptor affinity profile and pharmacokinetics are discussed. In addition, the ability to penetrate brain tissue has been studied for several compounds. As a typical example for these pyridine based S1P 1 agonists, compound 53 showed EC50 values of 0.6 and 352 nM for the S1P1 and S1P3 receptor, respectively, displayed favorable PK properties, and penetrated well into brain tissue. In the rat, compound 53 maximally reduced the blood lymphocyte count for at least 24 h after oral dosing of 3 mg/kg.

AMINOPYRAZINE DERIVATIVE AND MEDICINE

The present invention relates to a compound represented by general formula [1] satisfying the following (I) or (II), or a pharmaceutical acceptable salt of the compound. (I) X is CH or N; R1 is a halogen atom,; and R2 is H, a halogen atom, CN, [2], [3], [8], [9], an —O-alkyl, an —O-(saturated ring), etc. [2]: —C(RC)(RD)(RE) (RC to RE each are H, an alkyl, etc.) [3]: —N(RF)(RG) (RF and RG each are H, OH, amino, a (hetero)aryl, etc.) [8]: —C(═O)RL (RL is an alkyl, OH, an alkoxy, amino, etc.) [9]: a (substituted)phenyl; (II) X is >C—C(—O)R3 (R3 is a (substituted)amino, an alkoxy, OH, etc.); R1 is a halogen atom; R2 is H; R3 is H or OH; and R3 and R4 each are H or an alkyl.

2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS

The invention provides compounds of formula (I), and pharmaceutically and agriculturally acceptable salts thereof: wherein: R1, R2, R3, R4, R5, R6, R7, R8, A1, L1 and n are as defined herein. These compounds and their pharmaceutically acceptable salts are useful in the manufacture of medicaments for use in the prevention or treatment of a fungal disease. Compounds of formula (I), and agriculturally acceptable salts thereof, may also be used as agricultural fungicides.

NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES

The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS

The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims.

PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS

The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituants are as defined in the claims.

PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS

The invention relates to pyridine derivatives of Formula (I), wherein A, R1, R2, R3, R4, R5, R6 and R7 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.